Galapagos has developed a target discovery platform that provides novel starting points for drug and antibody therapies, thereby addressing the industry's need for innovative, disease-modifying medicines. Galapagos is exploiting this platform in disease areas for which there is a clear need for better medicines. The Company's product portfolio consists mainly of new mode-of-action drugs in bone and joint diseases as well as programs in cancer metastasis, cachexia and orphan diseases. To enable the progression of a broad portfolio of programs, Galapagos has established risk sharing alliances with big pharma companies in specific disease areas. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases.

Galapagos' service division, which includes BioFocus and the recently acquired service operations from Argenta, offers a full suite of target-to-drug discovery products and services to pharma, biotech and patient foundations - encompassing target and drug discovery through to the delivery of pre-clinical candidates
.


July 16, 2010
Galapagos and University of Bristol enter drug discovery collaboration in chronic pain
Read more

July 12, 2010
NIH extends agreement with Galapagos until end 2012
Read more

July 1, 2010
Servier and Galapagos initiate strategic alliance in osteoarthritis
Read more

Disclaimer
© Copyright 2010 Galapagos NV